Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Progressione della malattia cardiovascolare nei sopravvissuti alla polmonite acquisita in comunità e all'infezione polmonare da Covid-19. (HOMI-LUNG CAP)

5 novembre 2026 aggiornato da: Hellenic Institute for the Study of Sepsis

Uno studio non interventistico, prospettico e trasversale sulla progressione della malattia cardiovascolare nei sopravvissuti a polmonite acquisita in comunità e infezione polmonare da Sars-Cov-2

Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.

The overall concept underpinning "Homi-lung" is to investigate the time course of host-microbiome interactions during & after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment & CVRD history; iii) develop biomarkers to predict the individual response to the treatment & CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during & after pneumonia.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Post-acute pneumonia syndrome People believe that there is a "modern pandemic" beyond the pandemic. This is called the post-acute COVID syndrome (PACS), and it is a constellation of symptoms and medical entities which emerge after acute infection by the new coronavirus SARS-CoV-2 (COVID-19). However, in this definition, people are attracted by the apparent symptomatology and ignore that long-term complications may be even more severe. In this regard, it is reported that the incidence of type 2 diabetes mellitus (T2DM) is increasing almost 1.56-fold after acute COVID-19, which may happen without any symptoms. The increase in the incidence of T2DM is supported by two large-scale meta-analyses involving more than 4.2 million patients during the post-COVID-19 follow-up period.

Recent evidence from the Hellenic Sepsis Study group suggests that circulating monocytes of patients after the acute COVID- 19 illness have increased ability for the biosynthesis of interleukin (IL)-1β, many of them do not present symptoms of PACS.

Taking into consideration the importance of IL-1β for the pathogenesis of T2DM through the destruction of β-pancreatic cell islets, it is evident that increased cardiometabolic (CV) risk may also be a counterpart of PACS. In the CANTOS randomized clinical trial published several years ago, survivors of a first myocardial infarct were randomized to treatment with a placebo or canakinumab, one monoclonal antibody targeting IL-1β, for five years. Results showed that anti-IL-1 treatment decreased by 15% the incidence of secondary cardiovascular events outscoring excess IL-1β production as a driver of CV risk. Consequently, it is reasonable to hypothesize that COVID-19 survivors who over-produce IL-1β may present with long-term CV events.

Beyond state of the art: respiratory dysbiosis, a complete reappraisal of the physiopathology of pneumonia for innovative treatments Healthy distal airways have long been considered sterile, and pneumonia was thus supposed to be caused by the contamination of the lungs by exogenous virulent pathogens (for CAP) or during micro- aspirations of the digestive contents in comatose patients (for HAP). Based on this physiopathology, numerous strategies to rapidly eliminate pathogens are recommended and widely used in Europe and worldwide. However, the limits of CAP and HAP treatments which increase bacterial or viral clearance, are highlighted in almost all randomized trials evaluating antibiotics or antiviral drugs in which the rates of treatment failure commonly exceed 30%, and by the 30%-rate of patients presenting with prolonged symptoms after pathogen clearance. A reappraisal of the physiopathology of pneumonia seemed necessary to overcome the relative failure and improve patient outcomes.

We have demonstrated that pneumonia outcomes depend on pathogen clearance and restoring healthy interactions between a weakened microbiome and altered immunity. Since CVRD progression is associated with disruption of the host-microbiome interactions, we hypothesize that the dysbiosis induced by pneumonia participates in the CVRD progression reported after the infection recovery. We thus propose to perform i) a longitudinal follow-up of host-microbiome interactions in large cohorts of patients cured of pneumonia to demonstrate clinically meaningful associations between immune reprogramming, microbiome dysbiosis and CVRD progression, and ii) preclinical investigations in calibrated mice models to demonstrate causality between dysbiosis and CVRD progression.

It is now well established that airways harbour a rich and diverse microbiome in healthy controls. Respiratory tract invasion by pathogens rapidly causes a loss of microbiome diversity and an impoverishment of host-microbiome interactions. These respiratory microbiome alterations play an essential role in the development of lung inflammation during pneumonia and reflect variation in baseline lung innate immunity. In published studies of mechanically ventilated patients, it has been demonstrated that lung microbiota are correlated with alveolar inflammation and that disruption of the gut microbiome (via anti-anaerobic antibiotics) increases patients risk of prolonged mechanical ventilation and mortality. These studies demonstrate the clinical significance of the microbiome in recovery from lung injury. Alterations of the gut microbiome derived metabolites also participate in the long-term immune reprogramming observed after sepsis.

In the healthy state, respiratory mucosal immunity actively controls the commensal bacterial agents in the airways. Numerous studies have revealed profound immune alterations in septic patients, considered immunocompetent" at the time of hospitalization. Partner Nantes Université has demonstrated that pneumonia induces prolonged immune reprogramming, characterized by the formation of paralyzed dendritic cells (DCs) and low phagocytic alveolar macrophages (MAC), that lasts for months in humans and is associated with prolonged susceptibility to bacterial and viral respiratory infections. These results demonstrate that the required immune response to contain respiratory pathogens and interact with the microbiome is rapidly dampened during pneumonia and that this immune reprogramming lasts for years.

Critically ill patients are highly variable in their recovery from lung injury. Much of this variation is attributable to the differential recovery of alveolar epithelial cell integrity and function. An improved understanding of lung epithelial recovery will be necessary to identify therapeutic targets for resolving lung injury and preventing CVRD progression. Lung epithelial cells are subject to constant exposure to 1) microbiota within the respiratory tract and 2) metabolites and translocated bacterial products from the lower gut microbiome. Yet the role of the microbiome in alveolar epithelial recovery is undetermined.

As a summary, we propose a reappraisal of the physiopathology of pneumonia based on the concept of dysbiosis between a weakened microbiome and sepsis-induced immunosuppression, which have the potential to explain the prolonged susceptibility to non-communicable diseases, notably by sustaining epithelial injuries.

Role of host-microbiome interactions in CVRD progression Current pharmaceutical interventions designed to slow the progression of atherosclerosis focus almost exclusively on reducing plasma cholesterol levels. However, clinical and experimental data support an additional critical role for inflammation in atherothrombosis. Notably, inflammation inhibition targeting the central NLRP3 inflammasome to IL-1 to IL-6 pathway of innate immunity is an emerging method for atherosclerosis treatment and prevention. Macrophage accumulation within the vascular wall is a hallmark of atherosclerosis, and in atherosclerotic lesions, macrophages respond to various environmental stimuli, such as modified lipids and cytokines. We have demonstrated that trained immunity develops early during pneumonia, correlates with the inflammatory response, and can help to predict long-term outcomes after viral pneumonia.

This innate immune reprogramming, lasts for months after sepsis recovery and is characterized by exacerbated inflammatory response and prolonged decrease phagocytic activity of monocytes and macrophages during secondary immune stimulation. We thus propose that the functional reprogramming of monocytes and macrophages observed after pneumonia, can alter the control of atherosclerosis plaques, increasing the risk of major CVD events. The gut microbiome has also emerged as a central factor affecting type 2 diabetes, obesity and the progression of atherosclerotic cardiovascular disease.

Integration of host-microbiome interactions to model the response to pneumonia and identify patients at risk of unfavourable outcomes early Each patient likely responds differently to therapeutic intervention and might recover differently after pneumonia. Indeed, some subgroups of patients suffer rapid CVRD progression, and others return to baseline conditions. Several biomarkers have been associated with pneumonia outcomes, but none have reached the accuracy required for clinical implementation. This is mainly because they are usually developed in small mono-centre cohorts and analyzed separately in the microbiome and host status. So, pneumonia treatments and rehabilitation care are "one-fits-all patients" approach leading to a large proportion of treatment failures and CVRD progression.

There is a critical need for reliable biomarkers for the stratification of patients predicting therapy success/failure and risk of CVRD progression/severe. The gold standard to reach these objectives is to use large cohorts of patients, bar coding of the samples, and high-throughput analysis followed by unbiased algorithm-guided analysis. In this setting, the description that the integration of the host response and the microbiome composition have a fair accuracy for the diagnosis of pneumonia demonstrates the potential of protocols investigating the host/microbiome interactions for the development of personalized treatment for respiratory infections.

The development and validation of endotypes to better understand the functional mechanisms associated with CVRD progression will help clinicians to adapt treatment and better prevent these conditions. The definition of phenotypes will also help identify patients at risk early. We thus propose to combine host background (sex/gender, age, ethnicity, medical history and genetic susceptibility, vaccination), CVRD risk factors (dyslipidemia, diabetes, obesity), inflammation and soluble mediators (metabolome, cytokines), immune status (epigenetic regulation) and microbiome composition during and after pneumonia to capture the complexity of the hostmicrobiome interaction time course and define endotypes and phenotypes associating pneumonia with CVRD.

Tipo di studio

Osservativo

Iscrizione (Stimato)

650

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Prof. Evangelos Giamarellos-Bourboulis
  • Numero di telefono: 00302105831994
  • Email: egiamarel@med.uoa.gr

Luoghi di studio

      • Alexandroupoli, Grecia
        • Non ancora reclutamento
        • 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
        • Contatto:
          • Assoc. Prof. Periklis Panagopoulos
          • Numero di telefono: 00302551351592
          • Email: ppanago@med.duth.gr
      • Athens, Grecia
        • Reclutamento
        • Intensive Care Unit, General Hospital of Voula ASKLEPIEIO
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 4th Department of Internal Medicine, ATTIKON University General Hospital
        • Contatto:
          • Prof. Evangelos Giamarellos-Bourboulis
          • Numero di telefono: 00302105831994
          • Email: egiamarel@med.uoa.gr
      • Athens, Grecia
        • Reclutamento
        • 1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 3rd University Department of Internal Medicine, Sotiria Athens Hospital of Chest Diseases
        • Contatto:
          • Assoc. Prof. Garyfallia Poulakou
          • Numero di telefono: 00302107763439
          • Email: gpoulakou@gmail.com
      • Athens, Grecia
        • Reclutamento
        • 1st University Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • Out-patients clinic, General Hospital of Voula ASKLEPIEIO
        • Contatto:
          • Dr Sofia Nikolakopoulou
          • Numero di telefono: 00306944479683
          • Email: sofnikol@yahoo.gr
      • Athens, Grecia
        • Reclutamento
        • 1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 1st University Department of Internal Medicine, General Hospital of Athens LAIKO
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 1st Intensive Care Clinic of the Medical School of the University of Athens, Evangelismos General Hospital
        • Contatto:
          • Prof. Ioannis Kalomenidis
          • Numero di telefono: 00302132043307
          • Email: ikalom@med.uoa.gr
      • Athens, Grecia
        • Reclutamento
        • 2nd Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS
        • Contatto:
      • Athens, Grecia
        • Reclutamento
        • 2nd Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO
        • Contatto:
      • Elefsina, Grecia
        • Reclutamento
        • 1st Department of Internal Medicine, Thriasio General Hospital of Elefsina
        • Contatto:
      • Pátrai, Grecia
        • Non ancora reclutamento
        • Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA
        • Contatto:
          • Prof. Karolina Akinosoglou
          • Numero di telefono: 00302613603582
          • Email: akin@upatras.gr
      • Thessaloniki, Grecia
        • Non ancora reclutamento
        • Intensive Care Unit 2, AHEPA University General Hospital of Thessaloniki
        • Contatto:
      • Thessaloniki, Grecia
        • Non ancora reclutamento
        • Intensive Care Unit, "Ippokrateion" General Hospital of Thessaloniki
        • Contatto:
      • Thessaloniki, Grecia
        • Non ancora reclutamento
        • 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

The study needs to enroll four groups of patients to cover the magnitude of the spectrum of community-acquired pneumonia and enroll the required controls:

  • Group A: Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia. This group is important to provide baseline biological values and control samples to investigate normal host-microbiome interactions. No follow-up is performed for healthy controls.
  • Group B: Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia. This group is important to provide normal CVRD progression in patients at risk and control samples for the investigation of host-microbiome interactions in patients with stable CVRD.
  • Group C: Patients cured of acute COVID-19.
  • Group D: Patients cured of severe community-acquired pneumonia.

Descrizione

Inclusion Criteria:

Group A (healthy controls)

  1. Adults (18 years or more) of both genders (Female/Male: 50/50 ratio)
  2. No history of severe pneumonia (sCAP, COVID-19 or HAP)
  3. Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD.

Group B (CVRD controls)

  1. Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  2. No history of severe pneumonia (sCAP, COVID-19 or HAP)
  3. At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD

Group C (COVID-19 survivors)

  1. Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  2. Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia
  3. SoC treatment for acute COVID-19 with dexamethasone

Group D (sCAP survivors)

  1. Adults (18 years or more) of both genders
  2. Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit.
  3. SoC treatment for sCAP with antibiotics

Exclusion Criteria:

Group A (healthy controls)

  1. Presence of two or more comorbidities
  2. Any other co-existing disorder generating CVRD symptoms
  3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  4. Pregnancy or lactation

Group B (CVRD controls)

  1. Any other co-existing disorder generating CVRD symptoms
  2. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  3. Pregnancy or lactation

Group C (COVID-19 survivors)

  1. Medical history of severe congestive heart failure (Stage III-IV)
  2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
  3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  4. Pregnancy or lactation

Group D (sCAP survivors)

  1. Medical history of severe congestive heart failure (Stage III-IV)
  2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP
  3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  4. Pregnancy or lactation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: OTHER
  • Prospettive temporali: CROSS_SECTIONAL

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Healthy controls

Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia.

Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

CVRD controls

Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia

Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

  • Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

  • ECG, Heart ultrasound and cardiopulmonary exercise stress testing:

    • NYHA
    • Rhythm or conduction abnormality (yes/no)
    • Left ventricular ejection fraction (%)
    • VO2Max
COVID-19 survivors

Patients cured of acute COVID-19

Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

  • Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

  • ECG, Heart ultrasound and cardiopulmonary exercise stress testing:

    • NYHA
    • Rhythm or conduction abnormality (yes/no)
    • Left ventricular ejection fraction (%)
    • VO2Max
sCAP survivors

Patients cured of severe community-acquired pneumonia

Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

  • Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

  • ECG, Heart ultrasound and cardiopulmonary exercise stress testing:

    • NYHA
    • Rhythm or conduction abnormality (yes/no)
    • Left ventricular ejection fraction (%)
    • VO2Max

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The first primary outcome is the rates of major cardiovascular disease event at 6 months.
Lasso di tempo: From enrollment to Month 6.

Major CVD events are all-cause mortality, stroke, non-fatal acute coronary syndrome, pulmonary embolism or venous thrombosis

From enrollment to Month 6.
The second primary endpoint is poor cardiorespiratory fitness at 36 months.
Lasso di tempo: From enrollment to Month 36.

Poor fitness is a VO2max lower than normal values for age.

From enrollment to Month 36.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rates of unplanned hospitalisation
Lasso di tempo: From enrollment to Month 36.

Rates of unplanned hospitalisation

From enrollment to Month 36.
Rates of COPD exacerbation, hospitalization for respiratory failure and/or respiratory-related mortality at 3 years
Lasso di tempo: From enrollment to Month 36.

Rates of COPD exacerbation, hospitalization for respiratory failure and/or respiratory-related mortality at 3 years

From enrollment to Month 36.
Rates of secondary episodes of pneumonia, the incidence of non-respiratory infections
Lasso di tempo: From enrollment to Month 36.

Rates of secondary episodes of pneumonia, the incidence of non-respiratory infections

From enrollment to Month 36.
The rates of major cardiovascular disease event and of poor cardiorespiratory fitness
Lasso di tempo: At 6 and 36 months

The rates of major cardiovascular disease event at 6 months and of poor cardiorespiratory fitness at 36 months according to the microbiology of sCAP (viral vs bacterial vs mixed etiology)

At 6 and 36 months
The rates of major cardiovascular disease event and of poor cardiorespiratory fitness
Lasso di tempo: At 6 and 36 months

The rates of major cardiovascular disease event at 6 months and of poor cardiorespiratory fitness at 36 months according to the antibiotic treatments for sCAP

At 6 and 36 months
Changes in health-related quality of life (HRQoL)
Lasso di tempo: From six (M6) to eighteen months (M18) after hospital discharge

Changes in health-related quality of life (HRQoL) from six (M6) to eighteen months (M18) after hospital discharge measured with the Short Form (SF)-36 scale validated in Greek and Spanish

From six (M6) to eighteen months (M18) after hospital discharge
Changes in anxiety and depression
Lasso di tempo: From Month 6 to Month 18

Changes in anxiety and depression from M6 to M18, measured with the Hospital Anxiety and Depression Scale (HADS) validated in Greek and Spanish

From Month 6 to Month 18
Changes in subjective well-being
Lasso di tempo: From Month 6 to Month 18

Changes in subjective well-being from M6 to M18 measured with the Satisfaction With Life Scale (SWLS) validated in Greek and Spanish.

From Month 6 to Month 18
New metabolic disease
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

New metabolic disease, as evaluated by laboratory tests: diabetes (HbA1c > 6.5%), dyslipidemia, denutrition (pre-albumin and albumin blood levels) at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18
Distance at the 6-min walk-test
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

Distance at the 6-min walk-test at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18
Mean values of lung functions
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

Mean values of lung functions (maximum expiratory volume per second, vital capacity, expiratory reserve volume and inspiratory reserved volume, DLC50) at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18
Cardiopulmonary exercise stress testing
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

Cardiopulmonary exercise stress testing: VO2Max at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18
ECG: Percentages of patients with rhythm cardiac alterations, repolarisation abnormality
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

ECG: Percentages of patients with rhythm cardiac alterations, repolarisation abnormality at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18
Mean values of left ventricular ejection fraction
Lasso di tempo: At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

Mean values of left ventricular ejection fraction at hospital discharge, M6 and M18

At hospital discharge (i.e. an average of 1 Month after enrollment), Month 6 and Month18

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Prof. Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Study of Sepsis

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 novembre 2024

Completamento primario (Stimato)

8 novembre 2027

Completamento dello studio (Stimato)

8 giugno 2028

Date di iscrizione allo studio

Primo inviato

16 settembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

17 settembre 2024

Primo Inserito (Effettivo)

19 settembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2025

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HOMI-LUNG CAP

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .